Objective To systematically evaluate the clinical effectiveness and safety of capecitabine plus docetaxel in the treatment of patients with metastatic breast cancer where anthracycline has failed as a treatment.
Methods We electronically searched PubMed, EMBASE, the Cochrane Library (2008, issue 4), and CBM to Sept. 2008. Randomized controlled trials (RCTs) and quasi-RCTs about capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with metastatic breast cancer were identified. Study selection and analyses were undertaken according to the Cochrane Handbook, and RevMan 5.0 was applied for statistical analyses. The following was studied: total survival time, the development time of disease, reaction rate, the mid-survival time, adverse events and quality of life.
Results Three RCTs involving 672 patients with metastatic breast cancer were included. The results of meta-analyses showed that the overall survival (MD=3.00, 95%CI 1.64 to 4.36), disease time to progression (MD=1.85, 95%CI 1.15 to 2.55), and the response rate (RR=1.29, 95%CI 1.09 to 1.52) were superior in the combination arm to the docetaxel alone arm.
Conclusion The current evidence available shows that the combination of capecitabine and docetaxel may significantly improve the short-term efficacy comparing with docetaxel alone. However, adverse events and long-term efficacy are not clear; more high-quality RCTs should be conducted.
Citation：
LI Yali,XIAO Jialing,YANG Kehu,MA Bin. Capecitabine plus Docetaxel for Metastatic Breast Cancer: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2009, 09(8): 893-898. doi: 10.7507/1672-2531.20090157
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
Wold Health Organization. Breast cancer. 2008 Jan [cited 2009 Jun 10], Available from URL:http://www.euro.who.int/reproductivehealth/areas/20071101_6?language=French.
|
| 2. |
方芳. 乳腺癌放疗患者放射性皮肤损伤的护理进展. 现代护理, 2005, 11(7): 523-524.
|
| 3. |
刘冰冰, 位嘉, 付丽. 几种乳腺癌转移性相关基因的研究进展. 中华病理学杂志, 2008, 37(4): 266-269.
|
| 4. |
朱青山, 刘基巍, 陈雅敏. 多西他赛联合希罗达治疗蒽环类失败的转移性乳腺癌的临床研究. 实用癌症杂志, 2006, 21: 163-164.
|
| 5. |
胡夕春. 卡培他滨治疗乳腺癌进展. 中国医学论坛报, 2008 Jul 3.
|
| 6. |
陈建国. 药理学. 第2版. 北京: 科学出版社, 2007. 375.
|
| 7. |
Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 1960, 20: 37-46.
|
| 8. |
O’Shaughnessy J, Miles D, Vukelia S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Clin Oncol, 2002, 20(12): 2812-2823.
|
| 9. |
Beslija S, Obralic N, Basic H, et al. A single institution randomized trial of taxotere (T) and xeloda (X) given in combination vs. taxotere (t) followed by xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC). European Journal of Cancer, 2005, CN-00613834.
|
| 10. |
李明毅, 林大任, 谭洁媚. 卡培他滨联合多西紫杉醇治疗蒽环类耐药的转移性乳腺癌31例. 中华肿瘤防治杂志, 2006, 13(3): 216-217.
|
| 11. |
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. [www.cochrane-handbook.org/]. Accessed 10 March 2009.
|
- 1. Wold Health Organization. Breast cancer. 2008 Jan [cited 2009 Jun 10], Available from URL:http://www.euro.who.int/reproductivehealth/areas/20071101_6?language=French.
- 2. 方芳. 乳腺癌放疗患者放射性皮肤损伤的护理进展. 现代护理, 2005, 11(7): 523-524.
- 3. 刘冰冰, 位嘉, 付丽. 几种乳腺癌转移性相关基因的研究进展. 中华病理学杂志, 2008, 37(4): 266-269.
- 4. 朱青山, 刘基巍, 陈雅敏. 多西他赛联合希罗达治疗蒽环类失败的转移性乳腺癌的临床研究. 实用癌症杂志, 2006, 21: 163-164.
- 5. 胡夕春. 卡培他滨治疗乳腺癌进展. 中国医学论坛报, 2008 Jul 3.
- 6. 陈建国. 药理学. 第2版. 北京: 科学出版社, 2007. 375.
- 7. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 1960, 20: 37-46.
- 8. O’Shaughnessy J, Miles D, Vukelia S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Clin Oncol, 2002, 20(12): 2812-2823.
- 9. Beslija S, Obralic N, Basic H, et al. A single institution randomized trial of taxotere (T) and xeloda (X) given in combination vs. taxotere (t) followed by xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC). European Journal of Cancer, 2005, CN-00613834.
- 10. 李明毅, 林大任, 谭洁媚. 卡培他滨联合多西紫杉醇治疗蒽环类耐药的转移性乳腺癌31例. 中华肿瘤防治杂志, 2006, 13(3): 216-217.
- 11. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. [www.cochrane-handbook.org/]. Accessed 10 March 2009.
